DearDr.A.L.
WewouldliketointroduceourLungCancerDiagnosticKit(TellgenCorp.,China)thatisCFDA/CEIVDapprovedandcanbeaveryvaluableadditiontoSKMCHtestingrepertoire.
我们在此诚挚向您推荐透景公司全新推出的肺癌检测试剂盒，本试剂盒已获CFDA/CEIVD认证，对于贵机构SKMCH来说将是一项非常有价值的检测。
Currentlythemajorityoflungcancerpatientsarediagnosedasadvanceddiseasesfornosensitiveandspecificbiomarkersexist,noninvasivebiomarkerswithhighsensitivityandspecificityareurgentlyneededinlungcancerdiagnosis.
目前，由于缺乏高特异性和灵敏度的生物标记物，大多数的肺癌病例被检测出来时都已处于晚期。肺癌诊断亟需一种具有更高特异性和灵敏度的非侵入性标志物。
Bronchoscopyisastandardprocedureofthediagnosticwork-upofpatientswithsuspectedlungcancerdespiteitslimiteddiagnosticaccuracy.Besides,epigeneticchangesthroughDNAmethylationplayanimportantroleintumorigenesis.TheaberrantmethylationoftheSHOX2andRASSF1Ainbronchoalveolarlavagefluid(BALF)isproventobeaveryreliablemethodfordetectionofLungCancer.
支气管镜检查是对疑似肺癌患者诊断的标准程序，但其诊断的准确性有限。DNA甲基化引起的表观遗传学改变在肿瘤的发生过程中起着重要作用，通过对支气管肺泡灌洗液（BALF）中的SHOX2和RASSF1A基因进行甲基化检测，可为肺癌诊断提供更准确可靠的的补充依据。
Thiskitshowedsignificantsuperioritytocytologicaldiagnosis,astwoverificationstudiesdemonstrated.Inthestudyconductedbyaspecialhospitalforthoracicdiseaseswhere10,casesofbronchoscopeswereperformedannually,thesensitivityofcytologicalandDNAmethylationdiagnosiswere68.3%and81%respectively.AnotherstudycarriedoutinaGeneralhospital,where1,casesofbronchoscopeswereperformedannually,indicatedthatthesensitivityofcytologyexaminationwasonly5.7%,whilethesensitivityofDNAmethylationdiagnosiscanreach71.5%.Promisingly,theDNAmethylationtestwillbeapowerfulsupplementtotestingrepertoiresforthosehospitalswithweakfiberbronchoscopictechniquesandpathologicaldiagnosis.
研究表明，该试剂盒提供的方法与细胞学诊断相比具有突出优势：在某医院（每年施行纤支气管镜10例）开展的一项研究中，结果显示细胞学诊断灵敏度为68.3%，甲基化诊断灵敏度81.0%。而在另一家年施行纤支气管镜1医院，细胞学诊断灵敏度只有5.7%，但甲基化诊断灵敏度也可达到71.5%。可见，甲基化检测对纤支气管镜技术和病医院将是一种非常有力的补充。
Welookforwardtohearingfromyou.
Yoursfaithfully
S.G.A.
透景Lung-Me产品一经上市即吸引了业界广泛的